Normalized adjusted EBITDA(1) remained relatively stable at $59.4 million in the quarter, compared to $60.4 million in Q4-23.System sales(2) for ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

This proposed structure would allow the Company to enhance its production capabilities and operational efficiency while preserving cash, without affecting current market trading conditions. "This ...

Trump's de minimis delay leaves DTC brands in turmoil, struggling to plan amid sudden policy changes.